Biotech giant Bristol-Myers Squibb Company (BMY) is scheduled to report second-quarter 2025 results on July 31, before market ...

Bristol Myers Squibb BMY announced a strategic collaboration agreement with BioNTech BNTX for the global co-development and ...

Sotyktu (deucravacitinib) has been assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 6, 2026.

Bristol Myers (BMY) delivered an impressive performance in the past month after being under pressure for quite some time. The ...

Both companies have entered into an agreement for the global co-development and co-commercialization of BioNTech’s investigational bispecific antibody BNT327 across numerous solid tumor types.

Bristol-Myers Squibb faces structural headwinds from legacy product losses. Click here to find out why I upgrade my rating on BMY stock to a buy.

BioNTech SE (NASDAQ:BNTX) is one of the 13 Best German Stocks to Invest in Now. It is a clinical-stage biotechnology company focused on immunotherapies to treat cancer and other serious diseases ...

Read about BioNTech SE ADR (BNTX:XNAS) stock and today's latest news and financial updates.

Bristol Myers is making waves after a period of pressure. The stock jumped 6.3% recently, outperforming its industry and the ...

Summit Therapeutics' HARMONi trial data for ivonescimab showed a clinical benefit but narrowly missed statistical ...